Sunrest Lifescience has received a confirmed order worth Rs 9.22 crore from Gujarat Medical Services Corporation Limited (GMSCL), a domestic government procurement entity. The order will be executed through the company's subsidiary, Hetvi Lifesciences Private Limited, as disclosed to the exchange on 20 August 2026.

Order in Financial Context

Sunrest Lifescience is classified as an SME in the pharmaceuticals sector, with a market cap of Rs 72.35 crore as of 20 Aug 2026. At Rs 9.22 crore, this single order represents a meaningful contract relative to the company's overall scale. The consolidated trailing twelve-month revenue figure available in the provided data is Rs 0.0 crore, which prevents computation of standard metrics such as book-to-bill ratio (total disclosed order book divided by trailing twelve-month revenue) or backlog coverage in quarters. No pre-computed order book coverage or average quarterly revenue figures are available for this company. Readers should note these analytical limitations when assessing the order's relative weight.

No previous order disclosures are on record for Sunrest Lifescience in the last three fiscal quarters, so this filing represents the first disclosed order in the available history. This also means no total disclosed order book figure can be constructed from the standard three-quarter window.

Company Order Track Record

No order disclosures were found for Sunrest Lifescience in the last three fiscal quarters prior to this filing. As a result, no quarterly order inflow table can be presented, and it is not possible to assess whether inflow velocity is accelerating, stable, or decelerating. The Rs 9.22 crore award from Gujarat Medical Services Corporation Limited is the sole data point available in the disclosed history.

Execution and Revenue Quality

Quarterly revenue, net profit, and operating profit margin (OPM) data for the last three quarters are not available in the provided inputs. Execution trend analysis and margin quality assessment cannot be performed on the basis of the available data.

Revenue Growth - Order Wins Translating to Revenue

As Sunrest Lifescience has disclosed order activity, its standalone annual revenue has shown a mixed but broadly positive trajectory. Standalone revenue grew 12.3% year-on-year in FY25 and 19.5% in FY24, following a contraction of 8.3% in FY23. The FY25 profit growth of 786.0% on a standalone basis is notable in magnitude, though it follows a sharp 89.0% decline in FY24, indicating significant base effects rather than a smooth compounding trend. The available annual data does not allow a direct mapping of specific order wins to revenue recognition periods, given the absence of a multi-quarter order history.

Working Capital and Execution Capacity

Balance sheet and cashflow data are not available in the provided inputs for Sunrest Lifescience. Current ratio, total liabilities to equity, operating cashflow, and free cashflow figures cannot be assessed. Investors should seek the company's latest audited financials to evaluate whether the working capital position is adequate to support execution of this order through the subsidiary structure.

What to Watch

• Formal contract details: The filing describes the order as a "business execution and operational update" through subsidiary Hetvi Lifesciences Private Limited; further contract terms, milestones, or delivery schedules may be disclosed.
• Execution rate: Given the absence of a quarterly revenue run-rate, the pace at which this Rs 9.22 crore order converts to recognised revenue will be a key indicator to track in upcoming quarterly results.
• OPM trajectory: With no historical quarterly margin data available, the operating margin realised on this GMSCL contract will establish a reference point for assessing margin quality on government pharmaceutical supply orders.
• Client concentration: Gujarat Medical Services Corporation Limited is the sole disclosed awarding entity in the available history, making it the dominant client in the disclosed order book by default; any further diversification of the client base will be worth monitoring.

Key Observations

• Valuation check (as of 20 Aug 2026): P/E of 4.4x against ROCE of 14.12%. At the time of this article, the valuation appeared undemanding relative to the return ratio, with the stock trading below book value at a Price/Book of 0.99x. (P/E and Price/Book are price-derived and will change; ROCE is from audited financials)
• Promoter holding: Promoter stake has remained unchanged at 53.50% across Q2FY26, Q3FY26, Q4FY26, and Q1FY27, indicating no change in promoter position over the last four disclosed quarters.
• Subsidiary execution structure: The order is routed through Hetvi Lifesciences Private Limited, a subsidiary of Sunrest Lifescience. Revenue recognition and margin realisation at the consolidated level will depend on the subsidiary's execution capacity and intercompany accounting treatment.
• Standalone profit volatility: Standalone profit growth of 786.0% in FY25 follows an 89.0% decline in FY24, indicating high base-effect sensitivity in reported earnings rather than a stable compounding trend.

Sunrest Lifescience has announced a rights issue of 42,91,200 fully paid-up equity shares at an issue price of ₹35 per share, aiming to raise capital from its existing shareholder base. The Board of Directors approved the proposal during a meeting held on August 04, 2026, setting the record date for determining shareholder eligibility as August 10, 2026. This move effectively doubles the company’s outstanding share capital, increasing it from 42,91,200 shares to 85,82,400 shares upon full subscription.

The rights issue carries a premium of ₹25 per share over the face value of ₹10. Shareholders are entitled to one right equity share for every one fully paid-up equity share held on the record date. Eligible shareholders must pay the full amount at the time of application. The Board retains the authority to extend the issue period, provided it does not exceed 30 days from the opening date, and no withdrawals will be permitted after the closing date.

Schedule of Right Issue

Shareholders opting to renounce their rights through off-market transfers must ensure that the entitlements are credited to the renouncees’ demat accounts on or before the issue closing date. On-market renunciations can be completed until August 28, 2026.

Key Terms of the Issue

The announcement was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The detailed terms, including procedural guidelines, will be specified in the Letter of Offer sent to eligible shareholders in due course. This follows an earlier board meeting held on June 26, 2026, where the initial considerations for the rights issue were discussed.